DRUGS & SUPPLEMENTS
1 INDICATIONS AND USAGE
BiCNU Wafer is indicated for the treatment of patients with:
BiCNU Wafer is an alkylating drug indicated for the treatment of:
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dose
The recommended dose of BiCNU Wafer is eight 7.7 mg wafers for a total of 61.6 mg implanted intracranially. The safety and effectiveness of repeat administration have not been studied.
2.2 Insertion Instructions
Following maximal tumor resection, confirmation of tumor pathology and establishment of hemostasis, place up to a maximum of eight BiCNU Wafers to cover as much of the resection cavity as possible. Should the size and shape of the resected cavity not accommodate eight wafers, place the maximum number of wafers feasible within the cavity. Slight overlapping of the wafers is acceptable. Wafers broken in half may be used, but discard wafers broken in more than two pieces. Oxidized regenerated cellulose may be placed over the wafers to secure them against the cavity surface. After placement of the wafers, irrigate the resection cavity and close the dura in a water-tight fashion.
2.3 Preparation and Safe Handling
BiCNU Wafers contain a cytotoxic drug. Follow applicable special handling and disposal procedures.1
Each wafer is packaged within two nested aluminum foil laminate pouches. The inner pouch is sterile and is designed to maintain product sterility and protect the product from moisture. The outside surface of the outer laminated aluminum foil pouch is a peelable overwrap and is not sterile.
Deliver BiCNU Wafers to the operating room in their outer aluminum foil pouch, unopened. Do not open the pouch until the wafers are ready to be implanted. BiCNU Wafers in unopened outer foil pouches are stable at room temperature for six hours at a time for up to three cycles within a 30-day period.
Exposure to BiCNU can cause severe burning and hyperpigmentation of the skin. Use double gloves when handling BiCNU Wafers. Discard the outer gloves into a biohazard waste container after use. Use a dedicated surgical instrument for wafer implantation. If repeat neurosurgical intervention is indicated, handle residual wafers or wafer remnants as potential cytotoxic agents.
Instructions for Opening Pouch Containing BiCNU Wafer
Read all steps of the instructions prior to opening the pouch.
Instructions for opening the pouch containing BiCNU Wafer can be viewed at the following website: http://gliadel.com/hcp/pouch-opening-instructions. Illustrations are also pictured below.
Figure 1: To remove the sterile inner pouch from the outer pouch, locate the folded corner and slowly pull in an outward motion.
Figure 2: Do NOT pull in a downward motion rolling knuckles over the pouch. This may exert pressure on the wafer and cause it to break.
Figure 3: The inner pouch is a multi-layered, silver colored, foil laminate. Remove the inner pouch by grabbing hold of the crimped edge of the inner pouch using a sterile instrument and pulling upward.
Figure 4: To open the inner pouch, gently hold the crimped edge and cut in an arc-like fashion around the wafer.
Figure 5: To remove the BiCNU Wafer, gently grasp the wafer with the aid of forceps and place it onto a designated sterile field.
3 DOSAGE FORMS AND STRENGTHS
BiCNU Wafer is an off-white to pale yellow round wafer. Each BiCNU Wafer contains 7.7 mg of BiCNU.
5 WARNINGS AND PRECAUTIONS
Seizures occurred in 37% of patients treated with BiCNU Wafers for recurrent glioma in Study 2. New or worsening (treatment emergent) seizures occurred in 20% of patients; 54% of treatment emergent seizures occurred within the first 5 post-operative days . The median time to onset of the first new or worsened post-operative seizure was four days. Institute optimal anti-seizure therapy prior to surgery. Monitor patients for seizures postoperatively.
5.2 Intracranial Hypertension
Brain edema occurred in 23% of patients with newly diagnosed glioma treated with BiCNU Wafers in Study 1. Additionally, one GLIADEL-treated patient experienced intracerebral mass effect unresponsive to corticosteroids which led to brain herniation ). Monitor patients closely for intracranial hypertension related to brain edema, inflammation, or necrosis of the brain tissue surrounding the resection. In refractory cases, consider re-operation and removal of BiCNU Wafers or Wafer remnants.
5.3 Impaired Neurosurgical Wound Healing
Impaired neurosurgical wound healing including wound dehiscence, delayed wound healing, and subdural, subgleal, or wound effusions occur with BiCNU Wafer treatment. In Study 1, 16% of BiCNU Wafer-treated patients with newly diagnosed glioma experienced impaired intracranial wound healing and 5% had cerebrospinal fluid leaks. In Study 2, 14% of BiCNU Wafer-treated patients with recurrent glioma experienced wound healing abnormalities . Monitor patients post-operatively for impaired neurosurgical wound healing.
Meningitis occurred in 4% of patients with recurrent glioma receiving BiCNU Wafers in Study 2. Two cases of meningitis were bacterial; one patient required removal of the Wafers four days after implantation; the other developed meningitis following reoperation for recurrent tumor. One case was diagnosed as chemical meningitis and resolved following steroid treatment. In one case the cause was unspecified, but meningitis resolved following antibiotic treatment. Monitor postoperatively for signs of meningitis and central nervous system infection.
5.5 Wafer Migration
BiCNU Wafer migration can occur. To reduce the risk of obstructive hydrocephalus due to wafer migration into the ventricular system, close any communication larger than the diameter of a Wafer between the surgical resection cavity and the ventricular system prior to Wafer implantation. Monitor patients for signs of obstructive hydrocephalus.
5.6 Embryo-Fetal Toxicity
BiCNU Wafers can cause fetal harm when administered to a pregnant woman. BiCNU, the active component of BiCNU Wafer, is embryotoxic and teratogenic in rats at exposures less than the exposure at the recommended human dose on a mg/m2 basis and embryotoxic in rabbits at exposures similar to the exposure at the recommended human dose on a mg/m2 basis. Advise females of reproductive potential to avoid pregnancy after implantation of BiCNU Wafers. If the patient becomes pregnant after BiCNU Wafer implantation, warn the patient about the potential hazard to the fetus [see Use in Specific Populations (8.1 and 8.6) ].
6 ADVERSE REACTIONS
The following serious adverse reactions are discussed elsewhere in the label:
To report SUSPECTED ADVERSE REACTIONS, contact Arbor Pharmaceuticals, LLC at 1-866-516-4950 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Newly-Diagnosed High-Grade Malignant Glioma
The safety of BiCNU Wafers was evaluated in a multicenter, randomized (1:1), double-blind, placebo controlled trial of 240 adult patients with newly-diagnosed high-grade malignant glioma who received up to eight BiCNU Wafers or matched placebo implanted against the resection surfaces after maximal tumor resection (Study 1).
The population in Study 1 was 67% male and 97% White, and the median age was 53 years (range: 21-72). Eighty-seven percent had a Karnofsky performance status ≥ 70 and 71% had a Karnofsky performance status of ≥ 80%. Seventy-eight percent had a histologic subtype of glioblastoma multiforme as determined by central pathology review. Thirty-eight percent of patients received 8 wafers and 78% received ≥ 6 wafers. Starting three weeks after surgery, 80% of patients received standard limited field radiation therapy (RT) described as 55-60 Gy delivered in 28 to 30 fractions over six weeks; an additional 11% received no radiotherapy and the remainder received non-standard radiotherapy or a combination of standard and non-standard radiotherapy. At the time of progression, 12% received systemic chemotherapy.
Deaths occurred within 30 days of wafer implantation in 5 (4%) of patients receiving BiCNU Wafers compared to 2 (2%) of patients receiving placebo. Deaths on the BiCNU arm resulted from cerebral hematoma/edema (n=3), pulmonary embolism (n=1) and acute coronary event (n=1). Deaths on the placebo arm resulted from sepsis (n=1) and malignant disease (n=1).
The incidence of common adverse reactions in BiCNU Wafer-treated patients is listed in Table 1. The incidence of local adverse reactions is shown in Table 2.
Recurrent High-Grade Malignant Glioma
The safety of BiCNU Wafers was evaluated in a multicenter, randomized (1:1), double-blind, placebo controlled trial of 222 patients with recurrent high-grade malignant glioma who received up to eight BiCNU Wafers or matched placebo implanted against the resection surfaces after maximal tumor resection (Study 2). Patients were required to have had prior definitive external beam radiation therapy sufficient to disqualify them from additional radiation therapy. All patients were eligible to receive chemotherapy which was withheld at least four weeks (six weeks for nitrosoureas) prior to and two weeks after surgery.
The population in Study 2 was 64% male, 92% White, and the median age was 49 years (range: 19-80). Sixty-five percent had a histologic subtype of glioblastoma multiforme, 26% had anaplastic astrocytoma or another anaplastic variant, 73% had a Karnofsky performance status ≥ 70, 53% had a Karnofsky performance status of ≥ 80%, 73% had only one prior surgery, and 46% had prior treatment with nitrosourea. Eighty-one percent of patients received 8 wafers and 96% received ≥ 6 wafers.
Sixty-four severe adverse reactions were reported in 43(39%) patients receiving BiCNU Wafers. Adverse reactions in BiCNU Wafer-treated patients are shown in Table 3. Meningitis occurred in four patients receiving BiCNU Wafers and in no patients receiving placebo. Bacterial meningitis was confirmed in two patients: the first with onset four days following BiCNU Wafer implantation; the second following resection for tumor recurrence 155 days following BiCNU Wafer implantation. One case, attributed to chemical meningitis resolved following steroid treatment. The cause of the fourth case was undetermined but resolved following antibiotic treatment.
The incidence of seizures is shown in Table 4. The incidence of hydrocephalus, cerebral edema and intracranial hypertension is shown in Table 5.
8 USE IN SPECIFIC POPULATIONS
Pregnancy Category D
BiCNU Wafer can cause fetal harm when administered to a pregnant woman. There have been no studies with BiCNU Wafer; however, BiCNU, the active component of BiCNU Wafer, is embryotoxic and teratogenic in rats at exposures less than the exposure at the recommended human dose on a mg/m2 basis and embryotoxic in rabbits at exposures similar to exposures at the recommended human dose on a mg/m2 basis. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
There are no studies assessing the reproductive toxicity of BiCNU Wafer; however, BiCNU, the active component of BiCNU Wafer, is embryotoxic and teratogenic in rats at intraperitoneal doses of 0.5mg/kg/day or greater when given on gestation days 6 through 15. BiCNU caused fetal malformations (anophthalmia, micrognathia, omphalocele) at 1.0 mg/kg/day (about 0.12 the recommended human dose, eight wafers of 7.7 mg carmustine/wafer, on a mg/m2 basis). BiCNU was embryotoxic in rabbits at intravenous doses of 4.0 mg/kg/day (about 1.2 times the recommended human dose on a mg/m2 basis). Embryotoxicity was characterized by increased embryo-fetal deaths, reduced numbers of litters, and reduced litter sizes.
8.3 Nursing Mothers
It is not known if BiCNU, the active component of BiCNU Wafer, is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from BiCNU, a decision should be made whether to discontinue nursing or not to administer the drug, taking into account the importance of the drug to the mother.
8.4 Pediatric Use
The safety and effectiveness of BiCNU Wafer in pediatric patients have not been established.
8.5 Geriatric Use
Clinical trials of BiCNU Wafer did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients.
8.6 Females and Males of Reproductive Potential
BiCNU Wafer can cause fetal harm when administered during pregnancy (see Use in Specific Populations, 8.1 ). Counsel patients on pregnancy planning and prevention. Advise female patients of reproductive potential to use effective contraception after implantation of BiCNU Wafer. Advise patients to inform their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking BiCNU.
BiCNU caused testicular degeneration in animals. Advise male patients of the potential risk of infertility, and to seek counseling on fertility and family planning options prior to implantation of BiCNU Wafer. (see Nonclinical Toxicology, 13.1 )
BiCNU Wafer is an implant for intracranial use, containing BiCNU, a nitrosourea alkylating agent, and polifeprosan, a biodegradable copolymer used to control the release of BiCNU. It is a sterile, off-white to pale yellow wafer approximately 1.45 cm in diameter and 1 mm thick. Each wafer contains 7.7 mg of BiCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea, or BCNU] and 192.3 mg of a biodegradable polyanhydride copolymer. The copolymer, polifeprosan 20, consists of poly [bis (p-carboxyphenoxy)] propane and sebacic acid in a 20:80 molar ratio. BiCNU is homogeneously distributed in the copolymer matrix.
The structural formula for polifeprosan 20 is:
The structural formula for BiCNU is:
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
The activity of BiCNU Wafer is due to release of cytotoxic concentrations of BiCNU, a DNA and RNA alkylating agent, into the tumor resection cavity. On exposure to the aqueous environment of the resection cavity, the anhydride bonds in the copolymer are hydrolyzed, releasing BiCNU, carboxyphenoxypropane, and sebacic acid into the surrounding brain tissue.
BiCNU concentrations delivered by BiCNU Wafer in human brain tissue have not been determined.
Following an intravenous infusion of BiCNU at doses ranging from 30 to 170 mg/m2, the average terminal half-life, clearance and steady-state volume of distribution were 22 minutes, 56 mL/min/kg and 3.25 L/kg, respectively. Approximately 60% of the intravenous 200-mg/m2 dose of 14C-carmustine was excreted in the urine over 96 hours and 6% was expired as CO2. BiCNU degrades both spontaneously and metabolically. The relevance of these data to elimination of intracranial implant-delivered BiCNU are unknown.
BiCNU Wafers are biodegradable when implanted into the human brain. Wafer remnants may be observed on brain imaging scans or at re-operation. Wafer remnants were visible in 11 of 18 patients on CT scans obtained 49 days after implantation of BiCNU Wafer. More than 70% of the copolymer degrades within three weeks. Wafer remnants have been present at re-operation and autopsy up to 232 days after BiCNU Wafer implantation, and consisted mostly of water and monomeric components with minimal detectable BiCNU present.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
No carcinogenicity, mutagenicity, or impairment of fertility studies have been conducted with BiCNU Wafer. Carcinogenicity, mutagenicity, and impairment of fertility studies have been conducted with BiCNU, the active component of BiCNU Wafer. BiCNU was carcinogenic in rats and mice when delivered by intraperitoneal injection at doses lower than those delivered by BiCNU Wafer at the recommended dose. There were increases in tumor incidence in all treated animals. BiCNU was mutagenic in vitro (Ames assay, human lymphoblast HGPRT assay) and clastogenic both in vitro (V79 hamster cell micronucleus assay) and in vivo (SCE assay in rodent brain tumors, mouse bone marrow micronucleus assay).
In male rats BiCNU caused testicular degeneration at intraperitoneal doses of 8 mg/kg/week for eight weeks (about 1.3 times the recommended human dose on a mg/m2 basis).
14 CLINICAL STUDIES
14.1 Newly-Diagnosed High-Grade Malignant Glioma
Study 1 was a multicenter, double-blind, placebo-controlled, clinical trial in adult patients with newly-diagnosed high-grade malignant glioma. A total of 240 patients were randomized to receive up to eight BiCNU Wafers or matched placebo wafers following maximal tumor resection. Patients received post-operative radiation therapy (55-60 Gy delivered in 28 to 30 fractions over six weeks) starting three weeks after surgery. Patients with anaplastic oligodendroglioma also received systemic chemotherapy (6 cycles of PCV- lomustine 110 mg/m2 day 1, procarbazine 60 mg/m2 days 8-21, vincristine 1.4 mg/m2 days 8 and 29).
The population in Study 1 was 67% male and 97% White, and the median age was 53 years (range: 21-72). Eighty-seven percent had a Karnofsky performance status ≥ 70% and 71% had a Karnofsky performance status of ≥ 80%. Seventy-eight percent had a histologic subtype of glioblastoma multiforme as determined by central pathology review. Thirty-eight percent of patients received 8 wafers and 78% received ≥ 6 wafers. Starting three weeks after surgery, 80% of patients received standard limited field radiation therapy (RT) described as 55-60 Gy delivered in 28 to 30 fractions over six weeks; 11% received no radiotherapy and the remainder received non-standard radiotherapy or a combination of standard and non-standard radiotherapy. At the time of progression, 12% received systemic chemotherapy. Patients were followed for at least three years or until death.
Efficacy results for patients randomized in Study 1 are summarized in Table 6 and Figure 6. Overall survival among all patients with newly diagnosed high grade glioma, the primary outcome measure, was prolonged in the BiCNU arm. Overall survival in the subset of patients with glioblastoma multiforme, a secondary outcome measure, was not significantly prolonged.
14.2 Recurrent Glioblastoma Multiforme
Study 2 was a multicenter, double-blind, placebo controlled, clinical trial in adult patients with recurrent malignant glioma. Patients were required to have had prior definitive external beam radiation therapy sufficient to disqualify them from additional radiation therapy. Following maximal tumor resection and confirmation of malignant glioma, a total of 222 patients were randomized (1:1) to receive a maximum of eight BiCNU Wafers (n=110) or matched placebo wafers (n=112) positioned to cover the entire resection surface. All patients were eligible to receive chemotherapy which was withheld at least four weeks (six weeks for nitrosoureas) prior to and two weeks after surgery. Patients were followed for up to 71 months.
The population in Study 2 was 64% male and 92% White, and the median age was 49 years (range: 19-80). Sixty-five percent had a histologic subtype of glioblastoma multiforme, 26% had anaplastic astrocytoma or another anaplastic variant, 73% had a Karnofsky performance status ≥ 70, 53% had a Karnofsky performance status of ≥ 80%, 73% had only one prior surgery, and 46% had prior treatment with nitrosourea. Eighty-one percent of patients received 8 wafers and 96% received ≥ 6 wafers.
Survival and 6-month mortality rate in the subgroup of patients with recurrent glioblastoma multiforme, were exploratory outcome measures and are summarized in Table 7 and Figures 7 and 8. No survival prolongation was observed in patients with pathologic diagnoses other than glioblastoma multiforme.
16 HOW SUPPLIED/STORAGE AND HANDLING
BiCNU Wafer is supplied in a single dose treatment box containing eight individually pouched wafers. Each wafer contains 7.7 mg of BiCNU and is packaged in two aluminum foil laminate pouches. The inner pouch is sterile and is designed to maintain product sterility and protect the product from moisture. The outer pouch is a peelable overwrap. The outside surface of the outer pouch is not sterile.
NDC for single dose treatment box: 24338-050-08
Store BiCNU Wafer at or below -20ºC (-4ºF).
Do not keep unopened foil pouches at ambient room temperature for more than six hours at a time for up to three cycles within a 30-day period.
BiCNU Wafer is a cytotoxic drug and special handling and disposal procedures should be considered.1
17 PATIENT COUNSELING INFORMATION
Seizures: Advise patients to report any new or change in their seizure activity [(see Warnings and Precautions (5.1) ].
Intracranial Hypertension: Advise patients to report severe headaches, nausea, vomiting or new onset visual disturbances [(see Warnings and Precautions (5.2) ].
Impaired Neurosurgical Wound Healing: Advise patients to report any evidence of wound dehiscence, fever or cerebrospinal fluid leak .
Meningitis: Advise patients to report symptoms of meningitis such as fever or stiff neck .
Embryo-Fetal Toxicity: Counsel patients on pregnancy planning and prevention. Advise females of reproductive potential to use effective contraception during treatment with BiCNU .
Nursing Infants: Advise nursing mothers to discontinue nursing after BiCNU WAFER implantation .
Woodcliff Lake, NJ 07677
Arbor Pharmaceuticals, LLC
Atlanta, GA 30328
BiCNU® is a registered trademark of Eisai Inc.
BiCNU pharmaceutical active ingredients containing related brand and generic drugs:
Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.
BiCNU available forms, composition, doses:
Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.
BiCNU destination | category:
Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.
BiCNU Anatomical Therapeutic Chemical codes:
A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.
BiCNU pharmaceutical companies:
Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.
Frequently asked QuestionsCan i drive or operate heavy machine after consuming BiCNU?
Depending on the reaction of the BiCNU after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider BiCNU not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is BiCNU addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
Reviewsdrugs.com conducted a study on BiCNU, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of BiCNU consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.
Visitor reported usefulNo survey data has been collected yet
Visitor reported side effectsNo survey data has been collected yet
Visitor reported price estimatesNo survey data has been collected yet
Visitor reported frequency of useNo survey data has been collected yet
Visitor reported dosesNo survey data has been collected yet
Visitor reported time for resultsNo survey data has been collected yet
Visitor reported administrationNo survey data has been collected yet
Visitor reported ageNo survey data has been collected yet
The information was verified by Dr. Arunabha Ray, MD Pharmacology